Table 1 Correlation between tumoral B7-H3 and clinicopathological features of LUAD patients

Age (years)

0.485

 <60

24 (42.9%)

12 (38.7%)

12 (48.0%)

 ≥60

32 (57.1%)

19 (61.3%)

13 (52.0%)

Gender

0.320

 Male

31 (55.4%)

19 (61.3%)

12 (48.0%)

 Female

25 (44.6%)

12 (38.7%)

13 (52.0%)

Tumor size (mm)

0.651

 ≤30

22 (39.3%)

13 (41.9%)

9 (36.0%)

 >30

34 (60.7%)

18 (58.1%)

16 (64.0%)

Pathological stage

0.089

 III

16 (28.6%)

6 (19.4%)

10 (40.0%)

 IV

40 (71.4%)

25 (80.6%)

15 (60.0%)

EGFR mutation

0.931

 19 Del

31 (55.4%)

17 (54.8%)

14 (56.0%)

 21 L858R

25 (44.6%)

14 (45.2%)

11 (44.0%)

EGFR-TKIs

0.839^¶

 Gefitinib

30 (53.6%)

16 (51.6%)

14 (56.0%)

 Icotinib

22 (39.3%)

12 (38.7%)

10 (40.0%)

 Erlotinib

4 (7.1%)

3 (9.7%)

1 (4.0%)